IOL Chemicals & Pharmaceuticals delivered exceptional financial performance in the June 2026 quarter, with consolidated net profit rising 89.80% to ₹64.40 crore compared to ₹33.93 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a significant improvement in the company's bottom-line performance during the quarter ended June 2026.
The company's sales revenue increased 37.08% to ₹756.26 crore in the quarter ended June 2026, up from ₹551.69 crore in the same period last year. As reported by Business Standard, this substantial revenue growth demonstrates the company's strong operational performance and market expansion during the quarter.
The company's operating profit margin (OPM) stood at 13.68% in the June 2026 quarter, compared to 11.26% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this improvement in operating margins indicates enhanced operational efficiency and better cost management during the quarter.
Profit before tax (PBT) increased 90% to ₹86.69 crore in the June 2026 quarter compared to ₹45.51 crore in the previous year's corresponding quarter. Additionally, PBDT (Profit Before Depreciation and Tax) rose 65% to ₹108.03 crore from ₹65.28 crore in the June 2025 quarter, as reported by Business Standard.
